Key Publications

CN EN

Innovation

Dedicated to R&D of Medicines for
Respiratory and Pediatric Diseases

Broad antifibrotic activities of AK3280 in pulmonary, hepatic, cardiac, and skin fibrosis animal models

Gao, Zhao et al. International immunopharmacology. Apr 2025

More→
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up

Zhang, HanHu, Cilang et al. The Lancet Child & Adolescent Health. May 2025

More→
Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection

Zhao S, et al. The New England Journal of Medicine. September 2024

More→
Novel small-molecule inhibitors of SARS-CoV-2 main protease with nanomolar antiviral potency

Zhang H, et al. Journal of Infection. February 2024

More→
Current state and challenges in respiratory syncytial virus drug discovery and development

Zou G, et al. Antiviral Research. Jan 2024

More→
A protective human antibody against respiratory syncytial virus by targeting a prefusion epitope across sites IV and V of the viral fusion glycoprotein

Dai L, et al. hLife. November 2023

More→
Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial

Huang LM, et al. Influenza Other Respi Viruses. July 2023

More→
Discovery of Ziresovir as a Potent, Selective, and Orally Bioavailable Respiratory Syncytial Virus Fusion Protein Inhibitor

Zheng XF, et al. Journal of Medicinal Chemistry. July 2019

More→
Comparison of antiviral resistance across acute and chronic viral infections

Mason S, et al. Antiviral Research. October 2018

More→

Tel：+86-21-50681677
Address：No. 25, Lane 388, Shengrong Road, Pudong
New Area, Shanghai, China
E-mail：ir@arkbiosciences.com

Tel：+86-21-50681677
Address：No. 25, Lane 388, Shengrong Road, Pudong
New Area, Shanghai, China
E-mail：ir@arkbiosciences.com

Official account

        
HOME

TEL

TOP